For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of Vyndamax and Tafamidis meglumine represents a significant change. These novel therapies protect the transthyretin protein, slowing its harmful build-up and lessening the impact of the illness. People are now reporting improvements i